IL1B rs1143633: What Your Genotype Means for Psoriasis Treatment
The rs1143633 variant is a single nucleotide polymorphism located within the IL1B gene, which encodes a key pro-inflammatory cytokine. Research has investigated this variant for its potential role in influencing how patients with psoriasis respond to the medication apremilast.
What each genotype means
Typical IL1B genotype
This genotype represents one of the common variations in the IL1B gene. Research into the role of this variant in apremilast response for psoriasis is ongoing, and current evidence is limited regarding its specific impact on treatment outcomes. Please discuss any concerns about your medication response or dosing with your clinician or pharmacist.
This is a common genotype found across many global populations.
Typical IL1B genotype
This genotype represents one of the common variations in the IL1B gene. Research into the role of this variant in apremilast response for psoriasis is ongoing, and current evidence is limited regarding its specific impact on treatment outcomes. Please discuss any concerns about your medication response or dosing with your clinician or pharmacist.
This is a common genotype found across many global populations.
Typical IL1B genotype
This genotype represents one of the common variations in the IL1B gene. Research into the role of this variant in apremilast response for psoriasis is ongoing, and current evidence is limited regarding its specific impact on treatment outcomes. Please discuss any concerns about your medication response or dosing with your clinician or pharmacist.
This is a common genotype found across many global populations.
Understanding the rs1143633 Variant
The rs1143633 variant is a specific change in the DNA sequence of the IL1B gene, which is located on chromosome 2. In genetics, a single nucleotide polymorphism (SNP) like rs1143633 represents a variation at a single position in the DNA building blocks. This particular variant is categorized within the field of pharmacogenomics, which studies how an individual's genetic makeup influences their response to drugs. Because the IL1B gene is involved in regulating inflammation, researchers have long been interested in whether variations in this gene might explain why some individuals experience different outcomes when taking certain anti-inflammatory medications. It is important to note that while this variant is a subject of scientific interest, it is just one of many factors that can influence how a person responds to a medical treatment.
The Role of the IL1B Gene
The IL1B gene provides instructions for producing a protein called interleukin-1 beta. This protein is a potent pro-inflammatory cytokine, which acts as a signaling molecule to help the body manage immune responses. Produced primarily by activated macrophages, interleukin-1 beta plays a central role in the inflammatory process, influencing cell proliferation, differentiation, and apoptosis. Because it is a key mediator of inflammation, the IL1B gene is frequently studied in the context of chronic inflammatory conditions, such as psoriasis. Psoriasis is a complex, multifactorial disease characterized by skin inflammation and hyperproliferation. By understanding how the IL1B gene functions and how its variants might alter that function, scientists hope to gain better insights into the underlying biology of inflammatory diseases and potentially identify markers that could help predict how patients might respond to specific therapeutic interventions.
Research and Evidence Strength
The evidence linking rs1143633 to drug response is currently considered moderate. Most notably, a study involving a cohort of Russian patients with moderate-to-severe psoriasis explored the influence of various SNPs on the effectiveness of apremilast, a phosphodiesterase-4 inhibitor. In this specific study, patients carrying the minor allele of rs1143633 were observed to have a higher achievement of PASI75, a clinical measure of psoriasis improvement. However, it is crucial to interpret these findings with caution. Pharmacogenomic studies often involve small sample sizes, and results can vary significantly between different populations and ethnic groups. While these associations provide a foundation for further research, they do not currently serve as a definitive clinical tool for prescribing or dosing. The scientific community continues to investigate these markers to determine their reliability and clinical utility in personalized medicine.
Clinical Considerations and Next Steps
If you have information about your genotype for rs1143633, it is important to understand what you can and cannot do with this data. This information is for educational purposes and should never be used to make independent medical decisions, such as starting, stopping, or changing the dosage of a medication. Genetic markers are only one piece of a much larger puzzle that includes your overall health, medical history, and other environmental factors. If you are currently being treated for psoriasis or are considering a new treatment plan, the best course of action is to discuss your genetic information with your clinician or a pharmacist. They are equipped to interpret this data within the context of your specific health needs and can provide guidance on the most appropriate treatment strategies for your situation.
How common is this variant?
The rs1143633 variant is considered a common polymorphism, meaning the minor allele is present in a significant portion of the general population across various ancestries.
Frequently asked questions
What is the IL1B gene?
The IL1B gene provides instructions for making interleukin-1 beta, a protein that acts as a key signaling molecule in the body's inflammatory response.
Can I use my rs1143633 result to choose my psoriasis medication?
No. While research has studied this variant in the context of apremilast response, it is not currently used as a standard clinical test to guide medication selection. Always consult your doctor for treatment decisions.
Is rs1143633 a cause of psoriasis?
Psoriasis is a complex, multifactorial disease influenced by many genetic and environmental factors. rs1143633 is a genetic variant that may influence inflammatory pathways, but it is not considered a direct cause of the disease.
Where can I find more information about pharmacogenomics?
You can explore resources like PharmGKB or MedlinePlus Genetics for reliable, evidence-based information on how genes affect drug response.
Sources & further reading
Educational information only, last refreshed 9/28/2026. Not medical advice — these associations describe population statistics, not individual predictions.
Curious what your genotype is for rs1143633?
Upload a raw DNA file from 23andMe, AncestryDNA, MyHeritage, or FamilyTreeDNA and see this variant — plus thousands more — interpreted in your full report.
Get my report — $29Related variants in IL1B
Promoter single nucleotide polymorphism influencing baseline inducible interleukin-1 beta transcriptional activity and inflammatory response phenotypes.
Interleukin-1 beta variant that modulates the anti-inflammatory efficacy of dietary omega-3 polyunsaturated fatty acids and systemic inflammatory markers.
Promoter variant (c.-511C>T / c.-598C>T depending on transcript) in the IL1B gene extensively studied for regulatory influence on interleukin-1 beta expression and chronic inflammatory states.
Promoter regulatory single-nucleotide variant in interleukin-1 beta associated with altered inflammatory cytokine secretion and chronic inflammation predisposition.
This variant is associated with altered cytokine production and susceptibility to inflammatory conditions.